222 related articles for article (PubMed ID: 16504918)
1. The role of high-dose immune globulin intravenous in the treatment of dermatomyositis.
Dalakas MC
Int Immunopharmacol; 2006 Apr; 6(4):550-6. PubMed ID: 16504918
[TBL] [Abstract][Full Text] [Related]
2. High-dose intravenous immunoglobulin in inflammatory myopathies: experience based on controlled clinical trials.
Dalakas MC
Neurol Sci; 2003 Oct; 24 Suppl 4():S256-9. PubMed ID: 14598055
[TBL] [Abstract][Full Text] [Related]
3. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis.
Dalakas MC; Illa I; Dambrosia JM; Soueidan SA; Stein DP; Otero C; Dinsmore ST; McCrosky S
N Engl J Med; 1993 Dec; 329(27):1993-2000. PubMed ID: 8247075
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.
Raju R; Dalakas MC
Brain; 2005 Aug; 128(Pt 8):1887-96. PubMed ID: 15857930
[TBL] [Abstract][Full Text] [Related]
5. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments.
Basta M; Dalakas MC
J Clin Invest; 1994 Nov; 94(5):1729-35. PubMed ID: 7962520
[TBL] [Abstract][Full Text] [Related]
6. Clinical benefits and immunopathological correlates of intravenous immune globulin in the treatment of inflammatory myopathies.
Dalakas MC
Clin Exp Immunol; 1996 May; 104 Suppl 1():55-60. PubMed ID: 8625545
[TBL] [Abstract][Full Text] [Related]
7. [Intravenous immunoglobulins in the treatment of polymyositis and dermatomyositis].
Cherin P
Ann Med Interne (Paris); 2000 May; 151 Suppl 1():1S48-50. PubMed ID: 10896990
[TBL] [Abstract][Full Text] [Related]
8. [Intravenously-administered immunoglobulins as first-choice agent in juvenile dermatomyositis].
Breems DA; de Haas PW; Visscher F; Sabbe LJ; Busch HF; van Doorn PA
Ned Tijdschr Geneeskd; 1993 Sep; 137(39):1979-82. PubMed ID: 8413708
[TBL] [Abstract][Full Text] [Related]
9. [Immunoglobulins or plasma exchange? New treatment methods in polymyositis and dermatomyositis: plasma exchange and intravenous immunoglobulins].
Chérin P; Herson S
Ann Med Interne (Paris); 1993; 144(8):521-5. PubMed ID: 8179241
[TBL] [Abstract][Full Text] [Related]
10. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis.
Dalakas MC
Neurology; 1998 Dec; 51(6 Suppl 5):S37-45. PubMed ID: 9851729
[TBL] [Abstract][Full Text] [Related]
11. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile.
Dalakas MC
Pharmacol Ther; 2004 Jun; 102(3):177-93. PubMed ID: 15246245
[TBL] [Abstract][Full Text] [Related]
12. High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels.
Göttfried I; Seeber A; Anegg B; Rieger A; Stingl G; Volc-Platzer B
Eur J Dermatol; 2000; 10(1):29-35. PubMed ID: 10694294
[TBL] [Abstract][Full Text] [Related]
13. Update on the use of intravenous immune globulin in the treatment of patients with inflammatory muscle disease.
Dalakas MC
J Clin Immunol; 1995 Nov; 15(6 Suppl):70S-75S. PubMed ID: 8613495
[TBL] [Abstract][Full Text] [Related]
14. [Polymyositis: disease course and therapy with intravenously administered immunoglobulins].
Stoll T; Michel BA; Neidhart M; Wassmer P; Neidl K; Fehr K; Wagenhäuser FJ
Schweiz Med Wochenschr; 1992 Sep; 122(39):1458-65. PubMed ID: 1411405
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immunoglobulin therapy: magic or black magic.
Barron KS; Sher MR; Silverman ED
J Rheumatol Suppl; 1992 Apr; 33():94-7. PubMed ID: 1593608
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of intravenous Ig therapy in juvenile dermatomyositis.
Lam CG; Manlhiot C; Pullenayegum EM; Feldman BM
Ann Rheum Dis; 2011 Dec; 70(12):2089-94. PubMed ID: 21978999
[TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.
Dalakas MC
Clin Rev Allergy Immunol; 2005 Dec; 29(3):255-69. PubMed ID: 16391401
[TBL] [Abstract][Full Text] [Related]
18. Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis.
Luzi G; Diamanti AP; Germano V; Laganà B; Di Rosa R; Salemi S; Stoppacciaro A; D'Amelio R
Clin Immunol; 2007 Nov; 125(2):127-30. PubMed ID: 17720626
[TBL] [Abstract][Full Text] [Related]
19. [Two children with skin rash and muscle weakness: juvenile dermatomyositis].
Boogaard R; Drexhage VR; van Suijlekom-Smit LW
Ned Tijdschr Geneeskd; 2005 Jan; 149(3):146-50. PubMed ID: 15693592
[TBL] [Abstract][Full Text] [Related]
20. Spontaneously remitting dermatomyositis.
Jordan JR; Paruthi S; Pichardo RO; Challa VR; Donofrio PD; Jorizzo JL
J Eur Acad Dermatol Venereol; 2004 Jul; 18(4):495-8. PubMed ID: 15196172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
